OFEV (Nintedanib) Tablets: Uses, Dosage, Side Effects and Precautions?

 OFEV (Nintedanib) Tablets is a medication used to treat idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease that causes scarring of the lungs. It works by blocking certain enzymes that are involved in the formation of scar tissue in the lungs.


Here are some key facts about OFEV (Nintedanib) tablets:



Dosage: OFEV (Nintedanib) tablets are available in 100 mg and 150 mg doses. The recommended starting dose is 150 mg twice daily, taken with food.


Side effects: Like any medication, OFEV (Nintedanib) tablets can cause side effects. Some of the most common side effects include diarrhea, nausea, vomiting, decreased appetite, weight loss, and abdominal pain. If you experience any of these side effects, it's important to talk to your doctor.


Effectiveness: OFEV (Nintedanib) has been shown to slow the progression of IPF in clinical trials. In one study, patients taking OFEV (Nintedanib) had a 50% reduction in the rate of decline in lung function compared to those taking a placebo.


Monitoring: If you are taking OFEV (Nintedanib) tablets, your doctor will monitor you regularly to check your lung function and make sure the medication is working effectively. You may also need to have regular blood tests to check for any potential side effects.


Precautions: OFEV (Nintedanib) tablets are not recommended for pregnant or breastfeeding women, as the medication can cause harm to a developing fetus or nursing infant. It's important to let your doctor know if you are pregnant or planning to become pregnant while taking OFEV (Nintedanib).


In conclusion, OFEV (Nintedanib) tablets are an important medication for the treatment of idiopathic pulmonary fibrosis. While they can cause side effects, they have been shown to slow the progression of the disease and improve lung function in some patients. If you have been diagnosed with IPF, talk to your doctor to see if OFEV (Nintedanib) tablets may be a good treatment option for you.


Location: New Delhi, Delhi 110038, India

Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more